First Patient Dosed in Phase Ib/II Trial Evaluating Tiprelestat
tiakis Biotech AG announced today that a first patient has been dosed in the COMCOVID trial, a Phase Ib/II trial evaluating the Company’s key investigational product Tiprelestat. The COMCOVID trial is a nationwide study in Germany to evaluate safety and efficacy of Tiprelestat in hospitalized COVID-19 patients. The trial welcomes participation from additional study centers.
Tiprelestat is an anti-inflammatory human protein to be administered by intravenous infusion. It is anticipated that Tiprelestat, upon administration, will alleviate both pulmonary and systemic inflammation commonly associated with severe cases of COVID-19.
The randomized, double-blind, placebo-controlled Phase Ib/II trial is expected to enroll 296 patients receiving either Tiprelestat or placebo. Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19.
“We are pleased to announce that the first participant has been dosed in our latest clinical trial as we look to bring a potential new treatment option to severely affected COVID-19 patients,” says Diethelm Siebuhr, tiakis Biotech AG co-CEO.
The COMCOVID trial is co-funded by the Germany Ministry of Education and Research (“BMBF”) and tiakis is proud to support the ongoing efforts to develop treatment options for COVID-19 thereby lessening the future impact of the disease.